Capital gravitates toward key profitable mutual funds until the marginal asset return equilibrates near the core stock market benchmark.

Peter Prince

2019-07-27 17:37:00 Sat ET

Capital gravitates toward key profitable mutual funds until the marginal asset return equilibrates near the core stock market benchmark. As Stanford finance professor Jonathan Berk suggests, capital flows equilibrate persistent mutual fund returns relative to the stock market benchmarks. Since investors first direct capital to the best active mutual fund managers, these fund managers receive so much money that it affects their ability to generate superior returns. The average return declines to fit the average return for the second-best fund managers. At this stage, investors become indifferent to investing with the first-best and second-best fund managers, so capital flows equilibrate until their average return declines to match the average return for the third-best fund managers.

This process continues until the average return of investing in most active mutual funds declines to match the stock market benchmark. Capital flows can thus reflect persistent asset returns in the transition toward the dynamic equilibrium outcome. Only high-skill fund managers can consistently earn superior average returns when numerous fund managers compete for scarce capital flows. The rationale suggests that investors who choose to invest with active fund managers cannot expect to receive positive excess returns after we apply appropriate risk and fee adjustments.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Foreign majority owners offer Sprint and T-Mobile to stop using HuaWei critical technologies after the U.S. telecom merger.

Daphne Basel

2018-12-20 13:40:00 Thursday ET

Foreign majority owners offer Sprint and T-Mobile to stop using HuaWei critical technologies after the U.S. telecom merger.

T-Mobile and Sprint indicate that the U.S. is likely to approve their merger plan as they take the offer from foreign owners to stop using HuaWei telecom te

+See More

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fundamental analysis of T-Mobile (U.S. stock symbol: $TMUS).

James Campbell

2025-10-06 10:27:00 Monday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fundamental analysis of T-Mobile (U.S. stock symbol: $TMUS).

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund

+See More

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Dan Rochefort

2018-05-10 07:37:00 Thursday ET

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions in their recent corporate disclosures as of mid-2018. Georg

+See More

Google CEO Sundar Pichai makes his debut testimony before Congress.

John Fourier

2018-12-15 14:38:00 Saturday ET

Google CEO Sundar Pichai makes his debut testimony before Congress.

Google CEO Sundar Pichai makes his debut testimony before Congress. The post-mid-term-election House Judiciary Committee bombards Pichai with key questions

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

Former Vice President Joe Biden enters the next U.S. presidential race with many moderate policy proposals.

Monica McNeil

2019-05-05 10:34:00 Sunday ET

Former Vice President Joe Biden enters the next U.S. presidential race with many moderate policy proposals.

Former Vice President Joe Biden enters the next U.S. presidential race with many moderate-to-progressive policy proposals. At the age of 76, Biden stands ou

+See More